A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
← catalyst calendarNCT07710430 · readout in 1,107 d
Sponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
43estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-01 | estimated | When the study began enrolling |
| Primary completion | 2029-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Central Precocious Puberty
Intervention
- Drug: Leuprorelin
Primary outcome
what the primary-completion date above is the date OFPeak luteinizing hormone (LH) level following gonadotropin-releasing hormone (GnRH) stimulation is < 4 International Units per Liter (IU/L).
measured 24 weeks after treatment initiation
Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed